Core Viewpoint - The discovery of MARK2 as a physiological kinase for PER2 provides a new understanding of the molecular mechanisms behind circadian rhythm regulation and potential new targets for treating sleep disorders [4][17]. Group 1: Key Findings - MARK2 has been identified as the physiological kinase responsible for the phosphorylation of PER2 at the S662 site, which stabilizes the PER2 protein and extends the circadian rhythm cycle [8][12]. - The absence of MARK2 in neurons leads to an advanced activity phase and shortened circadian cycle in mice, mirroring symptoms seen in human familial advanced sleep phase syndrome (FASP) patients [12][13]. - Previous candidates for PER2 phosphorylation, including CK1δ, CK1ε, and others, did not produce the expected phase advance phenotype when knocked out, highlighting the unique role of MARK2 [9][12]. Group 2: Methodology - The research team utilized classical biochemical purification methods to isolate the active component capable of phosphorylating PER2 S662 from HEK293 cells, ultimately identifying MARK2 and MARK3 as the key players [11][12]. - Mass spectrometry confirmed that MARK2 and MARK3 could directly phosphorylate the S662 site of PER2, while other candidates did not exhibit this capability [11][12]. Group 3: Implications and Future Directions - The identification of MARK2 as a key regulator in circadian rhythm opens avenues for developing new treatments for sleep disorders by targeting MARK2 activity [17]. - The study suggests that the AMPK-related kinase (ARK) family may play a collective role in circadian regulation, warranting further exploration of their functions in broader physiological processes [15][17]. - Understanding the regulatory network of circadian rhythms could lead to more precise chronotherapy, optimizing drug administration timing to enhance efficacy and reduce side effects [17].